Modicus Prime Secures $1.1M in Pre-Seed Funding from Strategic Investors

Modicus Prime has announced the successful raise of a pre-seed round, which closed on 12/31/2022. The final investment was transferred on New Year’s Eve, marking the end of a breakout year for Modicus. The company accepted strategic investments from investors who will further expand Modicus Prime’s growth trajectory. These investors include the following venture capital firms, accelerators, angel groups, and strategic partners: Alumni Ventures, Valor Ventures, SmartGateVC, Flywheel Fund, Techstars, PlugandPlay, Dotmatics, Hero House Angels, B2 Enterprise, Ventures Elevated, New Capital Ventures, and CF2 Industries.

Modicus Prime welcomes Alumni Ventures, Valor Ventures, SmartGateVC, Flywheel Fund, Techstars, PlugandPlay, Dotmatics, Hero House Angels, B2 Enterprise, Ventures Elevated, New Capital Ventures, and CF2 Industries to its investor community.

The company emerged with a valuation of $10 million USD, and SAFE notes were the financial instrument used for the investments. The funding will be leveraged to support Modicus Prime’s growing customer base and team, which has doubled in size within the last year.

Edit: Since the publication of this article, Modicus Prime has welcomed Triple S Ventures with their $100K investment. The total pre-seed raise increased to $1.2M at a $10M valuation.

About Modicus Prime

Modicus Prime’s computer vision software automates biologics image analysis and is designed to solve for the cost, legal, and waste liabilities from product quality failures across R&D and manufacturing. Modicus Prime is venture-backed and has strategic partnerships with organizations including Takeda Pharmaceuticals, Oak Ridge National Laboratory (DOE), eLabNext (Eppendorf), Dotmatics, PlugandPlay Health, and Techstars. Our proprietary GxP-compliant software, mpVision, enables scientists to independently train their own AI to achieve real-time classification of any imaging data - from biologic morphology analysis to commercial contamination detection – for comprehensive quality control across R&D and manufacturing. mpVision has been globally tested by scientists at Takeda Pharmaceuticals, and its features are mapped to the unmet needs of the pharmaceutical industry, including real-time product quality assurance, full agency compliance, faster go-to-market, and reduced operating costs.

To learn more about Modicus Prime, please visit https://modicusprime.com.